RxDoctor Payments Data

Haley Harding

Primary Care · Scottsboro, ALNPI 1336683085

Payments from drug & device makers

$437in general payments, 2019–2025

Across 15 payments — averaging $29.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$175
  • AbbVie$75
  • Smith+Nephew$53
  • Lilly USA, LLC$51
  • GSK$40
  • Abbott$20
  • plus $23 from 2 others

What the payments were for

  • Consulting fees$17540%
  • Food & beverage$26260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$175
AbbVie5$75
Smith+Nephew1$53
Lilly USA, LLC3$51
GSK2$40
Abbott1$20
AstraZeneca1$12
Novo Nordisk1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$437 in reported general payments places this provider in the 40th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$7,629
Medicare patients
84
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide109$122,448
OzempicSemaglutide129$121,024
EliquisApixaban92$71,388
Tresiba Flextouch U-200Insulin Degludec50$38,131
JardianceEmpagliflozin57$37,803
TrulicityDulaglutide25$31,521
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$22,868
JanuviaSitagliptin Phosphate32$19,165
FarxigaDapagliflozin Propanediol25$16,193
RybelsusSemaglutide12$14,102
Combivent RespimatIpratropium/Albuterol Sulfate18$10,919
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$9,673
Humalog Kwikpen U-200Insulin Lispro14$9,317
LinzessLinaclotide13$8,692
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$51$153,969134 claims
Novo NordiskOzempic, Rybelsus$12$135,126141 claims
GSKTrelegy Ellipta, Breo Ellipta$40$28,56848 claims
AstraZenecaFarxiga, Breztri Aerosphere$12$24,23638 claims
AbbVieLinzess, Synthroid$75$10,17348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 159 primary care providers in Alabama.

Other primary care in Scottsboro

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →